2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki

from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH

We have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology question of the week from Dr. Emerson Chen of OHSU; and we sit down with Dr. Ali Khaki of the Fred Hutchinson Cancer Research Center to discuss his recent paper critiquing TAILORx. Pola for DLBCL: doi.org/10.1200/JCO.19.00172 Financial COI on Twitter: doi.org/10.1001/jamainternmed.2016.8467 Ignoring Valuable Data: doi.org/10.6004/jnccn.2019.7363 Back us on Patreon! www.patreon.com/plenarysession

Episode metadata supplied by the publisher feed · Published Jan 24, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki

0:00 1:32:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 1 hour and 32 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on January 24, 2020.

Can I download this Plenary Session - inactive due to federal service episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!